Istalab DM 500 is a powerful triple-drug formulation designed to manage Type 2 Diabetes Mellitus in adults, especially when single or dual therapy is insufficient to achieve adequate glycemic control. This advanced combination of Dapagliflozin, Metformin (Extended Release), and Sitagliptin offers a multifaceted approach to blood sugar regulation, helping patients maintain optimal glucose levels throughout the day.
Dapagliflozin is a selective SGLT2 (sodium-glucose co-transporter 2) inhibitor. It works by preventing glucose reabsorption in the kidneys and promotes its excretion through urine, thus reducing blood sugar levels independently of insulin. It also supports weight reduction and blood pressure control.
Metformin, a first-line antidiabetic agent, works primarily by reducing hepatic glucose production and improving the body’s sensitivity to insulin. The extended-release (ER) formulation allows for gradual drug release, improving gastrointestinal tolerance and maintaining consistent blood levels.
Sitagliptin is a DPP-4 (dipeptidyl peptidase-4) inhibitor. It enhances the body’s natural incretin hormones, increasing insulin production and reducing glucose output by the liver, especially after meals.
Together, these agents address multiple pathophysiological defects in Type 2 diabetes: insulin resistance, impaired insulin secretion, excessive hepatic glucose production, and increased glucose reabsorption by the kidneys. The result is comprehensive glucose control, improved HbA1c levels, and better long-term diabetic management.
Istalab DM 500 Tablet is typically recommended as an adjunct to diet and exercise and may also help reduce cardiovascular risk factors associated with diabetes. It is especially beneficial for patients needing stronger glycemic control without increasing the risk of hypoglycemia significantly.